The willingness of the elderly to take medication for primary cardiovascular disease prevention is relatively insensitive to its benefit but highly sensitive to its adverse effects, according to a recent study published in the Archives of Internal Medicine.
The willingness of the elderly to take medication for primary cardiovascular disease prevention is relatively insensitive to its benefit but highly sensitive to its adverse effects, according to a recent study published in the Archives of Internal Medicine.
Investigators interviewed 356 community-living elderly. Participants were asked about their willingness to take medication for the primary prevention of myocardial infarction (MI) according to its benefits (absolute 5-year risk reduction) and varying harms in terms of type and severity of adverse effects.
Among the participants, 88% were willing to take the medication if the benefit approximated the average risk reduction of currently available medications (an absolute benefit of 6 fewer persons with MI out of 100). Of the participants who would take the medication, 82% remained willing to do so if the absolute benefit was decreased to 3 fewer patients with MI; 17% of patients who would not take the medication changed their preference if the absolute benefit was increased to 10 fewer patients with MI.
Conversely, 48% to 69% of participants were unwilling or uncertain about taking medication with average benefit causing mild fatigue, nausea, or fuzzy thinking. When medication caused adverse effects severe enough to affect functioning, only 3% were willing to take it.
"These results suggest that clinical guidelines and decisions about prescribing these medications to older persons need to place emphasis on both their benefits and harms," concluded the authors.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More